Century Therapeutics To Present Initial Clinical Data Supporting The Potential For A Multi-Dosing Strategy For CAR iNK Enabled By Allo-Evasion Edits At The 65th ASH Annual Meeting And Exposition
Portfolio Pulse from Benzinga Newsdesk
Century Therapeutics, Inc. (NASDAQ:IPSC) announced the presentation of initial data from its Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas. The data supports the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits. The company's first allogeneic cell therapy product candidate, CNTY-101, is engineered with multiple functionalities designed to enhance its product profile. Preliminary data from a case study shows a complete response maintained in a patient following completion of four 28-day cycles of CNTY-101.
November 02, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Century Therapeutics' initial data from its Phase 1 trial of CNTY-101 supports the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits. This could potentially enhance the company's product profile and market position.
The initial data from Century Therapeutics' Phase 1 trial of CNTY-101 is positive, showing a complete response maintained in a patient following completion of four 28-day cycles of the therapy. This supports the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits, which could enhance the company's product profile and market position. This is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100